Meeting
2023 ASCO Annual Meeting
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
Authors
Stephanie L. Graff
Lifespan Cancer Institute, Providence, RI
Stephanie L. Graff , Sara M. Tolaney , Lowell L. Hart , Pedram Razavi , Peter A. Fasching , Wolfgang Janni , Lee S. Schwartzberg , Brad Lanoue , Tonatiuh Romero Salas , Aamir Khakwani , Courtney McDermott , Purnima Pathak , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 542)
DOI
10.1200/JCO.2023.41.16_suppl.542
Abstract #
542
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2022 ASCO Annual Meeting
Adherence to adjuvant endocrine therapy assessed by data from prescription renewals and medical records from tamoxifen in Swedish patients with cytochrome P450 2D6 (CYP2D6) genotyped early breast cancer.
First Author: Linda Thoren
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2019 ASCO Annual Meeting
The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.
First Author: Sara Bravaccini